ClinicalTrials.gg
CompletedNCT05393037Updated Feb 5, 2026Results posted

Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)

A Phase 3 interventional study of V116 and Placebo in Pneumococcal Disease, sponsored by Merck Sharp & Dohme LLC. Completed at 20 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
313
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections — 1 open to participants now, 2 under way, 2 of them phase 3. Pneumococcal 21-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
9th of 10
313 · median 1,075
Started
2022
with 3 others
Phase 3
9 of 10
1 open now
Registered
2nd of 10
by date
Lead sponsor
8 of 10
Merck Sharp & Dohme LLC

Among the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 9th largest by enrollment, is one of 4 that started in 2022, is one of 9 in phase 3, and was the 2nd registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

1 of the 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections is open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About Pneumococcal 21-Valent Conjugate Vaccine

Pneumococcal 21-Valent Conjugate Vaccine: first FDA approval 2024 (CAPVAXIVE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing Pneumococcal 21-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in persons living with human immunodeficiency virus (HIV), for the prevention of pneumococcal disease caused by the serotypes in the vaccine.

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is infected with
  • Is receiving combination anti-retroviral therapy (ART) for ≥6 weeks before study entry with no intended changes to combination ART therapy for 3 months after randomization.
  • Is vaccine-naïve

Exclusion criteria

Exclusion Criteria:

  • Has a history of opportunistic infections ≤12 months before the first vaccination
  • Has a history of noninfectious acquired immune deficiency syndrome-related illness
  • Has a history of active hepatitis
  • Has a history of invasive pneumococcal disease (IPD) or other culture-positive pneumococcal disease ≤3 years before Visit 2 (Day 1)
  • Has a known to any component of V116, PCV15, or PPSV23, including diphtheria toxoid
  • Has a known or suspected congenital immunodeficiency, functional or anatomic asplenia, or history of disease
  • Has a coagulation disorder contraindicating intramuscular vaccinations.
  • Has a recent illness with fever
  • Has a known cancer that is progressing or has required active treatment \<3 years before enrollment
  • Had prior administration of PCV15 or PCV20.
  • Is expected to receive any pneumococcal vaccine during the study outside of the protocol
  • Has received systemic for ≥14 consecutive days and has not completed treatment ≥14 days before receipt of study vaccine
  • Is currently receiving therapy, including chemotherapeutic agents or other immunotherapies/immunomodulators used to treat cancer or other conditions, and interventions associated with organ or bone marrow transplantation, or autoimmune disease
  • Has received any non- ≤14 days before receipt of any study vaccine or is scheduled to receive any non-live vaccine ≤30 days after receipt of any study vaccine
  • Has received any live virus vaccine ≤30 days before receipt of any study vaccine or is scheduled to receive any live virus vaccine ≤30 days after receipt of any study vaccine
  • Has received a blood transfusion or blood products, including immunoglobulins ≤6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product ≤30 days after receipt of study vaccine
  • Is currently participating in or has participated in an interventional clinical study with an compound or device within 2 months of participating in this current study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
313 participants (actual)

Study arms

  • Experimental
    V116 + Placebo

    Part A: Participants will receive a single intramuscular (IM) dose of V116 on Day 1, and a single IM dose of placebo on Week 8. Part B: Participants will receive a single IM dose of PCV15 between 10 to 18 months after V116.

    Biological: V116 · Biological: Placebo · Biological: PCV15 - Part B

  • Active comparator
    PCV15 + PPSV23

    Participants will receive a single IM dose of PCV15 on Day 1, and a single IM dose of PPSV23 on Week 8.

    Biological: PCV15 · Biological: PPSV23

Interventions

  • BiologicalV116

    Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

    Also known as: Pneumococcal 21-valent Conjugate Vaccine

  • BiologicalPlacebo

    Saline in each 0.5 mL sterile solution

  • BiologicalPCV15

    Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension

    Also known as: VAXNEUVANCE™;

  • BiologicalPPSV23

    Drug page: 23-valent pneumococcal capsular polysaccharide vaccine

    Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution

    Also known as: PNEUMOVAX™23

  • BiologicalPCV15 - Part B

    Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension

    Also known as: VAXNEUVANCE™

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Solicited Injection-site AEs From Day 1 Through Day 5 Postvaccination in Part A

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited injection-site AEs after any vaccination was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain.

    Time frame: Up to 5 days after each vaccination in Part A

  2. Percentage of Participants With Solicited Systemic AEs From Day 1 Through Day 5 Postvaccination in Part A

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited systemic AEs was assessed following any vaccination. The solicited systemic AEs assessed were fatigue, headache, myalgia, and pyrexia.

    Time frame: Up to 5 days after each vaccination in Part A

  3. Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through the Duration of Participation in Part A

    A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following any vaccination, the percentage of serious adverse events was assessed.

    Time frame: Up to 194 days in Part A

  4. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116

    Serotype-specific OPA to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were determined using a multiplex opsonophagocytic assay (MOPA). GMT is defined as geometric mean titer (1/dil). Serotype-specific OPA GMTs with 95% confidence intervals are presented.

    Time frame: Up to 114 days

Secondary outcomes

  1. Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116

    The GMC of IgG serotype-specific antibodies to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were quantitated from participants' sera by a multiplex electrochemiluminescence (ECL) assay.

    Time frame: Up to 114 days

  2. Serotype-specific OPA Geometric Mean Fold Rises (GMFRs) Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116

    Activity for the serotypes contained in V116 and PCV15+PPSV23 (13 serotypes shared with PCV15 and PPSV23 and 8 serotypes unique to V116) was determined using a Multiplexed Opsonophagocytic Assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination with V116 and PCV15 + PPSV23.

    Time frame: Baseline, 30 days post vaccination day 1 (V116), and 30 days post vaccination week 8 (PCV15 + PPSV23)

  3. Serotype-specific IgG GMFRs Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116

    The GMC of IgG serotype-specific antibodies to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were quantitated from participants' sera by a multiplex electrochemiluminescence (ECL) assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination with V116 and PCV15 + PPSV23

    Time frame: Baseline, 30 days post vaccination day 1 (V116), and 30 days post vaccination week 8 (PCV15 + PPSV23)

  4. Percentage of Participants With a >=4-fold Rise in OPA Responses From Baseline (Day 1) to Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116

    Activity for the serotypes contained in V116 and PCV15+PPSV23 (13 serotypes shared with PCV15 and PPSV23 and 8 serotypes unique to V116) was determined using MOPA. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination with V116 and PCV15 + PPSV23

    Time frame: Baseline, 30 days post vaccination day 1 (V116), and 30 days post vaccination week 8 (PCV15 + PPSV23)

  5. Percentage of Participants With a >=4-fold Rise in IgG Responses From Baseline (Day 1) to Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116

    The GMC of IgG serotype-specific antibodies to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were quantitated from participants' sera by a multiplex ECL assay. The percentage of participants who had ≥4-fold rise in IgG concentration was calculated from baseline to postvaccination with V116 and PCV15 + PPSV23

    Time frame: Baseline, 30 days post vaccination day 1 (V116), and 30 days post vaccination week 8 (PCV15 + PPSV23)

  6. Percentage of Participants With Solicited Injection-site AEs From Day 1 of Part B Through Day 5 Postvaccination in Part B

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited injection-site AEs after any vaccination was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain. Percentage of participants with solicited injection-site AEs from Day 1 of Part B through Day 5 postvaccination in Part B.

    Time frame: Up to 5 days after vaccination in Part B

  7. Percentage of Participants With Solicited Systemic AEs From Day 1 of Part B Through Day 5 Postvaccination in Part B

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited systemic AEs was assessed following any vaccination. The solicited systemic AEs assessed were fatigue, headache, myalgia, and pyrexia. Percentage of participants with solicited systemic AEs from Day 1 of Part B through Day 5 postvaccination in Part B

    Time frame: Up to 5 days after vaccination in Part B

  8. Percentage of Participants With Vaccine-related SAEs From Day 1 of Part B Through the Duration of Participation in Part B

    A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following any vaccination, the percentage of serious adverse events was assessed. Percentage of participants with vaccine-related SAEs from Day 1 of Part B through the duration of participation in Part B

    Time frame: Up to 44 days after vaccination in Part B

07

Results

Posted Jul 25, 2024

Participant flow

Part A
Participant flow — Part A
MilestoneV116 + Placebo (Part A), PCV15 (Part B)PCV15 + PPSV23 (Part A)
Started156157
Vaccination 1- v1161550
Vaccination 1- pcv151156
Vaccination 2- placebo1540
Vaccination 2-pcv1501
Vaccination 2-ppsv230151
Completed152152
Not completed45
Withdrew: Death10
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject24
Part B
Participant flow — Part B
MilestoneV116 + Placebo (Part A), PCV15 (Part B)PCV15 + PPSV23 (Part A)
Started1260
Completed1250
Not completed10
Withdrew: Lost to follow-up10

Outcome measures

PrimaryPercentage of Participants With Solicited Injection-site AEs From Day 1 Through Day 5 Postvaccination in Part A

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited injection-site AEs after any vaccination was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain.

Time frame:
Up to 5 days after each vaccination in Part A
Reported as:
Number · Percentage of Participants
Percentage of Participants With Solicited Injection-site AEs From Day 1 Through Day 5 Postvaccination in Part A
Percentage of ParticipantsV116 + Placebo (Part A), PCV15 (Part B)PCV15 + PPSV23 (Part A)
Injection site erythema3.9 (1.4 to 8.2)11.0 (6.5 to 17.0)
Injection site pain50.3 (42.2 to 58.4)82.6 (75.7 to 88.2)
Injection site swelling7.1 (3.6 to 12.3)20.6 (14.6 to 27.9)
PrimaryPercentage of Participants With Solicited Systemic AEs From Day 1 Through Day 5 Postvaccination in Part A

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited systemic AEs was assessed following any vaccination. The solicited systemic AEs assessed were fatigue, headache, myalgia, and pyrexia.

Time frame:
Up to 5 days after each vaccination in Part A
Reported as:
Number · Percentage of Participants
Percentage of Participants With Solicited Systemic AEs From Day 1 Through Day 5 Postvaccination in Part A
Percentage of ParticipantsV116 + Placebo (Part A)PCV15 + PPSV23 (Part A)
Fatigue30.3 (23.2 to 38.2)34.2 (26.8 to 42.2)
Headache21.9 (15.7 to 29.3)19.4 (13.5 to 26.5)
Myalgia12.3 (7.5 to 18.5)15.5 (10.2 to 22.2)
Pyrexia1.9 (0.4 to 5.6)3.2 (1.1 to 7.4)
PrimaryPercentage of Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through the Duration of Participation in Part A

A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following any vaccination, the percentage of serious adverse events was assessed.

Time frame:
Up to 194 days in Part A
Reported as:
Number · Percentage of Participants
Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through the Duration of Participation in Part A
Percentage of ParticipantsV116 + Placebo (Part A), PCV15 (Part B)PCV15 + PPSV23 (Part A)
Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) From Day 1 Through the Duration of Participation in Part A0.0 (0.0 to 2.4)0.0 (0.0 to 2.4)
PrimarySerotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116

Serotype-specific OPA to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were determined using a multiplex opsonophagocytic assay (MOPA). GMT is defined as geometric mean titer (1/dil). Serotype-specific OPA GMTs with 95% confidence intervals are presented.

Time frame:
Up to 114 days
Reported as:
Geometric mean · Titers
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMT) Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116
TitersV116 + Placebo (Part A), PCV15 (Part B)PCV15 + PPSV23 (Part A)
Serotype 3 (Shared)170.7 (132.5 to 220.0)172.0 (138.4 to 213.7)
Serotype 6A (Shared)3896.0 (2929.7 to 5181.1)3979.5 (3210.6 to 4932.5)
Serotype 7F (Shared)3482.3 (2815.8 to 4306.6)3275.6 (2658.1 to 4036.6)
Serotype 8 (Shared)1847.5 (1470.9 to 2320.6)2262.9 (1776.5 to 2882.5)
Serotype 9N (Shared)5763.0 (4552.8 to 7294.7)5970.0 (4786.9 to 7445.6)
Serotype 10A (Shared)3693.0 (2870.2 to 4751.5)3652.8 (2731.4 to 4885.1)
Serotype 11A (Shared)3742.5 (3050.7 to 4591.1)1722.3 (1277.1 to 2322.7)
Serotype 12F (Shared)2585.4 (1993.5 to 3353.0)2292.4 (1653.2 to 3178.8)
Serotype 17F (Shared)8698.6 (7046.1 to 10738.5)5886.3 (4489.8 to 7717.1)
Serotype 19A (Shared)2178.9 (1777.1 to 2671.7)2667.0 (2193.2 to 3243.1)
Serotype 20A (Shared)7249.1 (5854.9 to 8975.4)5753.3 (4634.0 to 7143.0)
Serotype 22F (Shared)3622.4 (2902.8 to 4520.4)3979.8 (3214.5 to 4927.1)
Serotype 33F (Shared)14642.5 (11314.9 to 18948.6)11864.5 (9283.8 to 15162.5)
Serotype 15A (Unique to V116)5859.0 (4684.9 to 7327.4)1970.5 (1555.1 to 2496.8)
Serotype 15C (Unique to V116)5613.0 (4136.7 to 7616.3)2438.0 (1791.5 to 3317.7)
Serotype 16F (Unique to V116)6703.0 (5494.0 to 8178.1)1839.0 (1474.3 to 2293.9)
Serotype 23A (Unique to V116)5053.5 (3781.3 to 6753.5)1674.9 (1209.9 to 2318.7)
Serotype 23B (Unique to V116)1593.8 (1182.7 to 2147.9)151.0 (98.1 to 232.6)
Serotype 24B (Unique to V116)3725.6 (3161.1 to 4391.0)567.9 (375.4 to 859.1)
Serotype 31 (Unique to V116)5699.4 (4435.1 to 7324.2)530.8 (364.2 to 773.7)
Serotype 35B (Unique to V116)11306.2 (9364.7 to 13650.1)2977.7 (2425.5 to 3655.8)
SecondarySerotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116

The GMC of IgG serotype-specific antibodies to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were quantitated from participants' sera by a multiplex electrochemiluminescence (ECL) assay.

Time frame:
Up to 114 days
Reported as:
Geometric mean · μg/mL
Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116
μg/mLV116 + Placebo (Part A), PCV15 (Part B)PCV15 + PPSV23 (Part A)
Serotype 3 (Shared)0.50 (0.43 to 0.59)0.58 (0.49 to 0.67)
Serotype 6A (Shared)3.79 (2.77 to 5.18)2.80 (2.02 to 3.89)
Serotype 7F (Shared)2.95 (2.31 to 3.77)1.81 (1.49 to 2.21)
Serotype 8 (Shared)7.05 (5.76 to 8.64)8.10 (6.66 to 9.85)
Serotype 9N (Shared)5.02 (4.01 to 6.28)3.36 (2.73 to 4.14)
Serotype 10A (Shared)7.15 (5.24 to 9.75)3.73 (2.78 to 5.00)
Serotype 11A (Shared)4.40 (3.55 to 5.45)2.64 (2.13 to 3.27)
Serotype 12F (Shared)1.10 (0.83 to 1.47)0.71 (0.51 to 0.99)
Serotype 17F (Shared)10.34 (8.24 to 12.96)4.43 (3.49 to 5.61)
Serotype 19A (Shared)5.96 (4.88 to 7.30)5.99 (4.83 to 7.43)
Serotype 20A (Shared)7.08 (5.60 to 8.95)4.94 (3.81 to 6.41)
Serotype 22F (Shared)3.70 (2.96 to 4.61)2.99 (2.40 to 3.72)
Serotype 33F (Shared)7.55 (5.90 to 9.65)5.56 (4.41 to 7.01)
Serotype 15A (Unique to V116)5.67 (4.37 to 7.36)1.02 (0.80 to 1.31)
Serotype 15C (Unique to V116)6.92 (5.15 to 9.29)2.68 (2.07 to 3.49)
Serotype 16F (Unique to V116)1.55 (1.23 to 1.95)0.21 (0.16 to 0.26)
Serotype 23F (Unique to V116)2.54 (1.85 to 3.50)0.41 (0.30 to 0.55)
Serotype 23B (Unique to V116)3.27 (2.51 to 4.25)0.99 (0.75 to 1.31)
Serotype 24F (Unique to V116)1.80 (1.25 to 2.59)0.17 (0.13 to 0.21)
Serotype 31 (Unique to V116)2.20 (1.78 to 2.72)0.25 (0.20 to 0.31)
Serotype 35B (Unique to V116)10.26 (7.96 to 13.22)0.90 (0.73 to 1.10)
SecondarySerotype-specific OPA Geometric Mean Fold Rises (GMFRs) Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116

Activity for the serotypes contained in V116 and PCV15+PPSV23 (13 serotypes shared with PCV15 and PPSV23 and 8 serotypes unique to V116) was determined using a Multiplexed Opsonophagocytic Assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination with V116 and PCV15 + PPSV23.

Time frame:
Baseline, 30 days post vaccination day 1 (V116), and 30 days post vaccination week 8 (PCV15 + PPSV23)
Reported as:
Geometric mean · Ratio
Serotype-specific OPA Geometric Mean Fold Rises (GMFRs) Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116
RatioV116 + Placebo (Part A), PCV15 (Part B)PCV15 + PPSV23 (Part A)
Serotype 3 (Shared)5.5 (4.3 to 7.1)5.3 (4.3 to 6.7)
Serotype 6A (Shared)14.3 (10.3 to 19.9)15.3 (11.3 to 20.7)
Serotype 7F (Shared)12.3 (9.1 to 16.3)7.4 (5.4 to 10.3)
Serotype 8 (Shared)11.9 (8.6 to 16.3)15.0 (10.4 to 21.8)
Serotype 9N (Shared)6.7 (5.0 to 8.9)5.9 (4.5 to 7.7)
Serotype 10A (Shared)9.4 (7.1 to 12.6)7.4 (5.4 to 10.2)
Serotype 11A (Shared)9.2 (6.4 to 13.4)3.8 (2.7 to 5.3)
Serotype 12F (Shared)57.3 (42.0 to 78.0)46.7 (31.4 to 69.4)
Serotype 17F (Shared)15.1 (11.2 to 20.2)8.5 (6.4 to 11.5)
Serotype 19A (Shared)5.0 (3.9 to 6.3)5.6 (4.4 to 7.2)
Serotype 20A (Shared)7.1 (5.5 to 9.2)4.7 (3.7 to 6.0)
Serotype 22F(Shared)19.2 (13.2 to 28.1)19.3 (12.7 to 29.4)
Serotype 33F (Shared)7.5 (5.6 to 10.1)6.8 (5.2 to 9.1)
Serotype 15A (Unique to V116)5.7 (4.2 to 7.7)1.4 (1.1 to 1.8)
Serotype 15C (Unique to V116)27.8 (18.7 to 41.4)16.3 (10.9 to 24.3)
Serotype 16F (Unique to V116)6.3 (4.8 to 8.2)1.7 (1.4 to 2.0)
Serotype 23A (Unique to V116)9.0 (6.0 to 13.7)2.8 (1.7 to 4.8)
Serotype 23B (Unique to V116)52.0 (35.7 to 75.6)7.2 (4.9 to 10.4)
Serotype 24F (Unique to V116)5.8 (4.0 to 8.3)1.0 (0.8 to 1.3)
Serotype 31 (Unique to V116)19.9 (13.8 to 28.6)1.5 (1.1 to 2.0)
Serotype 35B (Unique to V116)5.4 (4.3 to 6.8)1.3 (1.1 to 1.5)
SecondarySerotype-specific IgG GMFRs Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116

The GMC of IgG serotype-specific antibodies to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were quantitated from participants' sera by a multiplex electrochemiluminescence (ECL) assay. Geometric mean fold rise (GMFR) is the geometric mean of fold rise from baseline to postvaccination with V116 and PCV15 + PPSV23

Time frame:
Baseline, 30 days post vaccination day 1 (V116), and 30 days post vaccination week 8 (PCV15 + PPSV23)
Reported as:
Geometric mean · Ratio
Serotype-specific IgG GMFRs Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116
RatioV116 + Placebo (Part A), PCV15 (Part B)PCV15 + PPSV23 (Part A)
Serotype 3 (Shared)3.7 (3.2 to 4.3)4.0 (3.4 to 4.6)
Serotype 6A (Shared)11.4 (8.8 to 14.6)9.2 (7.1 to 11.8)
Serotype 7F (Shared)9.1 (7.3 to 11.3)5.7 (4.7 to 6.8)
Serotype 8 (Shared)8.1 (6.5 to 10.1)10.0 (7.9 to 12.8)
Serotype 9N (Shared)10.4 (8.3 to 13.0)7.8 (6.3 to 9.6)
Serotype 10A (Shared)12.2 (9.7 to 15.3)8.2 (6.7 to 10.0)
Serotype 11A (Shared)6.6 (5.5 to 7.9)4.5 (3.8 to 5.3)
Serotype 12F (Shared)9.7 (7.7 to 12.4)6.7 (5.1 to 8.8)
Serotype 17F (Shared)13.8 (11.1 to 17.1)7.5 (6.2 to 9.1)
Serotype 19A (Shared)3.8 (3.2 to 4.6)4.8 (4.1 to 5.6)
Serotype 20A (Shared)7.3 (6.0 to 8.9)5.4 (4.5 to 6.5)
Serotype 22F (Shared)13.7 (10.7 to 17.5)10.4 (8.4 to 13.0)
Serotype 33F (Shared)8.1 (6.6 to 10.0)5.9 (4.9 to 7.1)
Serotype 15A (unique to V116)16.1 (13.1 to 19.9)2.4 (2.1 to 2.8)
Serotype 15C (unique to V116)16.6 (13.3 to 20.8)6.1 (5.0 to 7.5)
Serotype 16F (unique to V116)8.8 (7.3 to 10.7)1.4 (1.3 to 1.6)
Serotype 23A (unique to V116)15.8 (12.3 to 20.3)2.8 (2.3 to 3.4)
Serotype 23B (unique to V116)10.0 (8.0 to 12.6)3.6 (2.9 to 4.4)
Serotype 24F (unique to V116)10.9 (8.3 to 14.2)1.0 (0.9 to 1.1)
Serotype 31 (unique to V116)11.6 (9.6 to 14.0)1.4 (1.3 to 1.6)
Serotype 35B (unique to V116)11.8 (9.4 to 14.7)1.1 (1.0 to 1.1)
SecondaryPercentage of Participants With a >=4-fold Rise in OPA Responses From Baseline (Day 1) to Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116

Activity for the serotypes contained in V116 and PCV15+PPSV23 (13 serotypes shared with PCV15 and PPSV23 and 8 serotypes unique to V116) was determined using MOPA. The percentage of participants who had ≥4-fold rise in OPA titers were calculated from baseline to postvaccination with V116 and PCV15 + PPSV23

Time frame:
Baseline, 30 days post vaccination day 1 (V116), and 30 days post vaccination week 8 (PCV15 + PPSV23)
Reported as:
Number · Percentage of Participants
Percentage of Participants With a >=4-fold Rise in OPA Responses From Baseline (Day 1) to Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116
Percentage of ParticipantsV116 + Placebo (Part A), PCV15 (Part B)PCV15 + PPSV23 (Part A)
Serotype 3 (Shared)58.7 (49.4 to 67.6)61.9 (52.5 to 70.6)
Serotype 6A (Shared)73.8 (65.0 to 81.3)80.2 (71.7 to 87.0)
Serotype 7F (Shared)69.0 (60.3 to 76.8)59.2 (49.8 to 68.0)
Serotype 8 (Shared)66.9 (58.3 to 74.7)70.1 (61.3 to 77.9)
Serotype 9N (Shared)56.3 (47.2 to 65.2)57.7 (48.5 to 66.6)
Serotype 10A (Shared)62.2 (53.2 to 70.7)60.5 (50.9 to 69.6)
Serotype 11A (Shared)53.6 (44.5 to 62.6)43.6 (34.4 to 53.1)
Serotype 12F (Shared)92.2 (86.1 to 96.2)83.3 (75.4 to 89.5)
Serotype 17F (Shared)77.1 (68.9 to 84.0)64.7 (55.4 to 73.2)
Serotype 19A (Shared)49.2 (40.4 to 58.1)55.9 (46.8 to 64.7)
Serotype 20A (Shared)59.2 (50.3 to 67.8)49.2 (40.1 to 58.3)
Serotype 22F (Shared)76.0 (67.4 to 83.3)71.7 (62.4 to 79.8)
Serotype 33F (Shared)61.9 (52.3 to 70.9)58.8 (49.4 to 67.8)
Serotype 15A (Unique to V116)59.3 (49.4 to 68.6)21.1 (14.0 to 29.7)
Serotype 16F (Unique to V116)53.6 (44.5 to 62.6)16.8 (10.6 to 24.8)
Serotype 23A (Unique to V116)57.9 (47.3 to 68.0)32.5 (22.2 to 44.1)
Serotype 23B (Unique to V116)87.0 (79.7 to 92.4)50.0 (40.7 to 59.3)
Serotype 24F (Unique to V116)53.8 (43.1 to 64.4)7.2 (2.4 to 16.1)
Serotype 31 (Unique to V116)73.7 (65.3 to 80.9)16.5 (10.4 to 24.4)
Serotype 35B (Unique to V116)55.6 (46.8 to 64.2)5.6 (2.3 to 11.2)
Serotype 15C (Unique to V116)80.4 (71.8 to 87.3)71.0 (61.5 to 79.4)
SecondaryPercentage of Participants With a >=4-fold Rise in IgG Responses From Baseline (Day 1) to Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116

The GMC of IgG serotype-specific antibodies to the 13 serotypes common between V116 and PCV15 + PPSV23 and 8 serotypes unique to V116 were quantitated from participants' sera by a multiplex ECL assay. The percentage of participants who had ≥4-fold rise in IgG concentration was calculated from baseline to postvaccination with V116 and PCV15 + PPSV23

Time frame:
Baseline, 30 days post vaccination day 1 (V116), and 30 days post vaccination week 8 (PCV15 + PPSV23)
Reported as:
Number · Percentage of participants
Percentage of Participants With a >=4-fold Rise in IgG Responses From Baseline (Day 1) to Postvaccination in Part A for 13 Serotypes Common Between V116 and PCV15 + PPSV23 and 8 Serotypes Unique to V116
Percentage of participantsV116 + Placebo (Part A), PCV15 (Part B)PCV15 + PPSV23 (Part A)
Serotype 3 (Shared)42.3 (33.9 to 51.1)50.4 (41.6 to 59.2)
Serotype 6A (Shared)70.8 (62.4 to 78.3)68.2 (59.5 to 76.0)
Serotype 7F (Shared)70.1 (61.7 to 77.6)57.9 (49.0 to 66.4)
Serotype 8 (Shared)66.4 (57.9 to 74.3)73.7 (65.3 to 80.9)
Serotype 9N (Shared)75.2 (67.1 to 82.2)67.7 (59.0 to 75.5)
Serotype 10A (Shared)76.6 (68.7 to 83.4)68.4 (59.8 to 76.2)
Serotype 11A (Shared)66.4 (57.9 to 74.3)54.1 (45.3 to 62.8)
Serotype 12F (Shared)67.9 (59.4 to 75.6)60.2 (51.3 to 68.5)
Serotype 17F (Shared)83.9 (76.7 to 89.7)73.7 (65.3 to 80.9)
Serotype 19A (Shared)43.8 (35.3 to 52.5)58.6 (49.8 to 67.1)
Serotype 20A (Shared)67.2 (58.6 to 74.9)57.1 (48.3 to 65.7)
Serotype 22F (Shared)76.6 (68.7 to 83.4)78.9 (71.0 to 85.5)
Serotype 33F (Shared)67.9 (59.4 to 75.6)63.2 (54.4 to 71.4)
Serotype 15A (Unique to V116)83.9 (76.7 to 89.7)21.8 (15.1 to 29.8)
Serotype 15C (Unique to V116)82.5 (75.1 to 88.4)61.7 (52.8 to 69.9)
Serotype 16F (Unique to V116)73.7 (65.5 to 80.9)9.0 (4.7 to 15.2)
Serotype 23A (Unique to V116)82.5 (75.1 to 88.4)29.3 (21.8 to 37.8)
Serotype 23B (Unique to V116)72.3 (64.0 to 79.6)37.6 (29.3 to 46.4)
Serotype 24F (Unique to V116)70.1 (61.7 to 77.6)0.0 (0.0 to 2.7)
Serotype 31 (Unique to V116)83.2 (75.9 to 89.0)6.8 (3.1 to 12.5)
Serotype 35B (Unique to V116)75.9 (67.9 to 82.8)0.8 (0.0 to 4.1)
SecondaryPercentage of Participants With Solicited Injection-site AEs From Day 1 of Part B Through Day 5 Postvaccination in Part B

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited injection-site AEs after any vaccination was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and tenderness/pain. Percentage of participants with solicited injection-site AEs from Day 1 of Part B through Day 5 postvaccination in Part B.

Time frame:
Up to 5 days after vaccination in Part B
Reported as:
Number · Percentage of Participants
Percentage of Participants With Solicited Injection-site AEs From Day 1 of Part B Through Day 5 Postvaccination in Part B
Percentage of ParticipantsV116 + Placebo (Part A), PCV15 (Part B)
Injection site erythema3.2 (0.9 to 7.9)
Injection site pain61.9 (52.8 to 70.4)
Injection site swelling6.3 (2.8 to 12.1)
SecondaryPercentage of Participants With Solicited Systemic AEs From Day 1 of Part B Through Day 5 Postvaccination in Part B

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with solicited systemic AEs was assessed following any vaccination. The solicited systemic AEs assessed were fatigue, headache, myalgia, and pyrexia. Percentage of participants with solicited systemic AEs from Day 1 of Part B through Day 5 postvaccination in Part B

Time frame:
Up to 5 days after vaccination in Part B
Reported as:
Number · Percentage of Participants
Percentage of Participants With Solicited Systemic AEs From Day 1 of Part B Through Day 5 Postvaccination in Part B
Percentage of ParticipantsV116 + Placebo (Part A), PCV15 (Part B)
Fatigue22.2 (15.3 to 30.5)
Headache14.3 (8.7 to 21.6)
Myalgia11.1 (6.2 to 17.9)
Pyrexia0.8 (0.0 to 4.3)
SecondaryPercentage of Participants With Vaccine-related SAEs From Day 1 of Part B Through the Duration of Participation in Part B

A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following any vaccination, the percentage of serious adverse events was assessed. Percentage of participants with vaccine-related SAEs from Day 1 of Part B through the duration of participation in Part B

Time frame:
Up to 44 days after vaccination in Part B
Reported as:
Number · Percentage of Participants
Percentage of Participants With Vaccine-related SAEs From Day 1 of Part B Through the Duration of Participation in Part B
Percentage of ParticipantsV116 + Placebo (Part A), PCV15 (Part B)
Percentage of Participants With Vaccine-related SAEs From Day 1 of Part B Through the Duration of Participation in Part B0.0 (0.0 to 2.9)

Adverse events

Collected over Part A - Non-serious adverse events (NSAEs): Up to 30 days after each vaccination; SAEs and all-cause mortality (ACM): Up to 194 days after the first vaccination Part B - NSAEs: Up to 30 days after vaccination; SAEs and ACM: Up to 44 days after vaccination. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
V116 + Placebo (Part A)1/156 (0.6%)4/155 (2.6%)96/155 (61.9%)
PCV15 + PPSV23 (Part A)0/157 (0%)6/155 (3.9%)136/155 (87.7%)
V116 + Placebo (Part A), PCV15 (Part B)0/126 (0%)1/126 (0.8%)82/126 (65.1%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventV116 + Placebo (Part A)PCV15 + PPSV23 (Part A)V116 + Placebo (Part A), PCV15 (Part B)
PresyncopeNervous system disorders0/1550/1551/126
Chest discomfortGeneral disorders1/1550/1550/126
DeathGeneral disorders1/1550/1550/126
Arthritis bacterialInfections and infestations0/1551/1550/126
NeurosyphilisInfections and infestations0/1551/1550/126
PneumoniaInfections and infestations0/1551/1550/126
Ankle fractureInjury, poisoning and procedural complications1/1550/1550/126
Diffuse large B-cell lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1551/1550/126
Metastases to meningesNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1551/1550/126
AphasiaNervous system disorders1/1550/1550/126
Most frequent other events
Most frequent other events
EventV116 + Placebo (Part A)PCV15 + PPSV23 (Part A)V116 + Placebo (Part A), PCV15 (Part B)
Injection site painGeneral disorders78/155128/15578/126
FatigueGeneral disorders47/15553/15528/126
HeadacheNervous system disorders38/15531/15519/126
Injection site swellingGeneral disorders11/15532/1558/126
MyalgiaMusculoskeletal and connective tissue disorders20/15524/15514/126
Injection site erythemaGeneral disorders6/15517/1550/126
DiarrhoeaGastrointestinal disorders2/1559/1550/126

Baseline characteristics

Age, Continuous
Age, Continuous(Years)V116 + Placebo (Part A), PCV15 (Part B)PCV15 + PPSV23 (Part A)Total
Mean44.0 ± 12.646.7 ± 12.345.3 ± 12.5
Sex: Female, Male
Sex: Female, Male(Participants)V116 + Placebo (Part A), PCV15 (Part B)PCV15 + PPSV23 (Part A)Total
Female425092
Male114107221
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)V116 + Placebo (Part A), PCV15 (Part B)PCV15 + PPSV23 (Part A)Total
Hispanic or Latino324476
Not Hispanic or Latino124112236
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)V116 + Placebo (Part A), PCV15 (Part B)PCV15 + PPSV23 (Part A)Total
American Indian or Alaska Native112
Asian211233
Native Hawaiian or Other Pacific Islander000
Black or African American6263125
White7079149
More than one race123
Unknown or Not Reported101
08

Study locations

20 sites
  • Pueblo Family Physicians ( Site 0014)
    Phoenix, Arizona 85015, United States
  • Whitman-Walker Institute ( Site 0009)
    Washington D.C., District of Columbia 20005, United States
  • Midway Immunology and Research Center ( Site 0003)
    Ft. Pierce, Florida 34982, United States
  • Orlando Immunology Center ( Site 0004)
    Orlando, Florida 32803, United States
  • KC CARE Health Center ( Site 0013)
    Kansas City, Missouri 64111, United States
  • North Texas Infectious Diseases Consultants, P.A ( Site 0001)
    Dallas, Texas 75246, United States
  • Texas Center for Infectious Disease Associates ( Site 0011)
    Fort Worth, Texas 76104, United States
  • CHU Saint-Pierre ( Site 0500)
    Brussels, Bruxelles-Capitale, Region de 1000, Belgium
  • Insituut voor tropische Geneeskunde ( Site 0501)
    Antwerp, 2000, Belgium
  • Hospital hernan henriquez aravena de temuco-Unidad de Investigación Clínica ( Site 0101)
    Temuco, Araucania 4781151, Chile
  • Universidad San Sebastian - Providencia ( Site 0111)
    Providencia, Region M. de Santiago 7500000, Chile
  • Universidad de Chile - Hospital Clínico Universidad de Chile ( Site 0107)
    Santiago, Region M. de Santiago 8380420, Chile
  • Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0601)
    Paris, 75014, France
  • Hôpital Saint-Louis ( Site 0600)
    Paris, Île-de-France Region 75010, France
  • Josha Research ( Site 0900)
    Bloemfontein, Free State 9300, South Africa
  • Perinatal HIV Research Unit (PHRU)-Adult Treatment and Research ( Site 0906)
    Johannesburg, Gauteng 1862, South Africa
  • Right To Care Research - Esizayo ( Site 0904)
    Johannesburg, Gauteng 2087, South Africa
  • Be Part Yoluntu Centre ( Site 0902)
    Paarl, Western Cape 7646, South Africa
  • Faculty of Medicine Siriraj Hospital-Preventive and social ( Site 1100)
    Bangkok, Bangkok 10700, Thailand
  • Research Institute for Health Sciences-Research Institute for Health Sciences Building 1 ( Site 1101
    Chiang Mai, 50200, Thailand
09

References and documents

Publications

  • Pathirana J, Ramgopal M, Martin C, Lombaard JJ, Chahin C, Launay O, Ratanasuwan W, Greenberg D, Grijalva CG, Orenstein WA, Shenkerman A, Hall L, Fernsler D, Kim Y, Li J, Platt HL; STRIDE-7 Study Group. Safety, tolerability, and immunogenicity of an adult-specific pneumococcal conjugate vaccine, V116, in people living with HIV (STRIDE-7): a two-part, parallel-group, randomised, active comparator-controlled, international, phase 3 trial. Lancet HIV. 2025 Oct;12(10):e679-e690. doi: 10.1016/S2352-3018(25)00165-1. Epub 2025 Sep 12. PubMed 40953572 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Jul 2023, 12 months.

Results were first posted in Jul 2024, 1 year after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 12 months is close to that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2022
First posted
May 26, 2022
StartActual
Jul 13, 2022
Primary completionActual
Jul 13, 2023
CompletionActual
Jan 25, 2024
Results first posted
Jul 25, 2024
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05393037
Responsible party
Sponsor
First posted
May 26, 2022
Start date
Jul 13, 2022
Primary completion
Jul 13, 2023
Completion
Jan 25, 2024
Results posted
Jul 25, 2024
Last update
Feb 5, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 21-Valent Conjugate Vaccine

Start the discussion